VA Pharma SRL
0.6 FTEThe score of VA Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +108 % Total assets +24 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
VA Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 58,359 € | ||||
| Equity | 409,268 € | ||||
| Cash | 298,103 € | ||||
| EBITDA | 126,750 € | ||||
| Total assets | 898,242 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 27 Aug 2026
- Year ended 31 Dec 2024filed on 01 Aug 2025
- Year ended 31 Dec 2023filed on 30 Aug 2024
- Year ended 31 Dec 2022filed on 29 May 2024
- Year ended 31 Dec 2021filed on 30 Aug 2022
VA Pharma's financial analysis
- Solvency45.6%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of VA Pharma
VA Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0508.521.312
- VAT number
- BE0508521312
- Peppol
- Registered · 0208:0508521312 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 18 Dec 2012
- Registered office
- 7133 Binche
- Size
- Micro · 0.6 FTE
- Latest accounts
- 2025 · filed on 27 Aug 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
VA Pharma (SRL) has been based in Binche since 2012, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 58,359 € and equity of 409,268 €; its revenue is not published. With 0.6 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 45.6%, above the median of its sector (41.5%).
Companies similar to VA Pharma
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie B. CROWET Retail sale of pharmaceutical products Binche · balance sheet 889,480 €
- Apotheek Desauw Retail sale of pharmaceutical products Kortrijk · balance sheet 897,867 €
- Stekene Pharma Retail sale of pharmaceutical products Stekene · balance sheet 898,762 €
- Pharmaplus Grand Place Retail sale of pharmaceutical products Tournai · balance sheet 896,066 €
- Pharmayou Glons Retail sale of pharmaceutical products Bassenge · balance sheet 901,766 €
- Novil'Pharma Retail sale of pharmaceutical products Fernelmont · balance sheet 907,966 €
- DE Vulder Retail sale of pharmaceutical products Roosdaal · balance sheet 887,085 €
- Pharmuny Retail sale of pharmaceutical products Ellezelles · balance sheet 909,631 €
Frequently asked questions about VA Pharma
What is the revenue of VA Pharma?
VA Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of VA Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0508521312 for VA Pharma, if the company is VAT-registered. Its company number (CBE) is 0508.521.312.
Where is the registered office of VA Pharma?
According to the CBE register, the registered office of VA Pharma is in 7133 Binche.
What is the equity of VA Pharma?
At the close of the 2025 financial year, the equity of VA Pharma amounts to 409,268 €, a solvency of 45.6% of total assets.
How many people work at VA Pharma?
0.6 full-time equivalents on average according to the 2025 social balance sheet.
Who manages VA Pharma?
The register lists 3 active mandates at VA Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of VA Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →